Friday, September 19, 2014 11:44:11 AM
The luncheon in Aspen was a full house to hear Dr Seymour. There were quite a few physicians
attending asking all about Ebola.
One question was asked about vaccine vs EbolaCide 2. The direct answer was that no vaccine would work completely because of the constant mutation of the virus. Dr Seymour said that the latest figures show over 400 mutations since the outbreak started according to Harvard. He is confident in EbolaCide 2 because of the ebola cellular receptor NPC1 being successfully mimicked and avoiding the decoys of the ebola virus.
Dr Seymour is departing shortly for Africa over the objections of his family. He has been asked by the President of an African country, Rwanda I believe, to meet and discuss treating small primates and lowland gorillas in the wild. This would be accomplished by using a specially designed dart gun to inject the animals. Most people are unaware of primates dying from ebola and if left unchecked a possible extinction. Furthermore the silverbacks could become infected and meet a similar fate.
After EbolaCide2 has been proven in the wild, Dr Seymour will ask the Govt. for 100 million to get the human program started. The" Breakthrough Drug Act" allows for this.
About tox, Dr Seymour and I had a short discussion after his presentation and he said all the material has been made to ship to Basi and he is going to announce the commencement of tox testing very shortly.
About plant production quantities, that is the responsibility of the production managers who deal with
that day to day. Dr Seymour has no hard numbers to respond to.
Another announcement Dr Seymour made was about Oral Flucide. The production would be handled by a plant in Texas. This will occur after injectables are established.
According to Dr Seymour, the market cap for NNVC when EbolaCide 2 is proven will be 1 billion. This is coming soon.
L vus
Recent NNVC News
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 10/15/2024 08:44:44 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/27/2024 08:15:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/09/2024 08:30:39 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 08/09/2024 08:05:25 PM
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
SANUWAVE Announces Record Quarterly Revenues: Q3 FY2024 Financial Results • SNWV • Nov 8, 2024 7:07 AM
DBG Pays Off $1.3 Million in Convertible Notes, which Retires All of the Company's Convertible Notes • DBGI • Nov 7, 2024 2:16 PM
SMX and FinGo Enter Into Collaboration Mandate to Develop a Joint 'Physical to Digital' Platform Service • SMX • Nov 7, 2024 8:48 AM
Rainmaker Worldwide Inc. (OTC: RAKR) Announces Successful Implementation of 1.6 Million Liter Per Day Wastewater Treatment Project in Iraq • RAKR • Nov 7, 2024 8:30 AM
SBC Medical Group Holdings and MEDIROM Healthcare Technologies Announce Business Alliance • SBC • Nov 7, 2024 7:00 AM
VAYK Confirms Insider Buying at Open Market • VAYK • Nov 5, 2024 10:40 AM